Randox provides the Gold Standard in renal damage testing – Cystatin C

July 14, 2010 - PRLog -- The Predictive Safety Testing Consortium (PSTC) has provided data which supports the use of various renal markers, including Cystatin C, in a preclinical setting. The biomarkers have been shown to outperform traditional markers, such as creatinine and blood urea nitrogen (BUN), in both specificity and sensitivity. Cystatin C and many other renal damage biomarkers are available from Randox Laboratories.

Due to drug-induced toxicity being such a serious issue, it is vital that quality preclinical toxicity biomarkers are available to avoid such affected products being marketed and reaching the consumer. A recent report from the PSTC set out to discover what makes a good safety biomarker. They concluded; “first, the marker must be present in peripheral body tissue and/or fluid (e.g., blood, urine, saliva, breath or cerebrospinal fluid); second, it must be easy to detect or quantify in assays that are both affordable and robust; and third, its appearance must be associated as specifically as possible with damage of a particular tissue, preferably in a quantifiable manner.”

It was noted that the traditional renal damage markers; creatinine and BUN conform only to the first two of these three critical criteria. However it has now been accepted by regulators that the following biomarkers are superior in specificity and sensitivity:

•   Cystatin C
•   Albumin
•   Total protein
•   Β2-microglobulin

As further confirmation, the study stated; “Between June 2007 and January 2008, these data were presented to the authorities, which by April 2008 had accepted that these biomarkers outperformed the current standards.”

Randox Laboratories has nearly 30 years experience in providing the highest quality clinical diagnostic reagents for use in laboratories worldwide. All of the above mentioned biomarkers are included in our comprehensive portfolio, therefore enabling a reliable diagnosis of renal damage. Ensure your laboratory is using the gold standard and achieving results you can trust. Randox is at the cutting-edge of laboratory medicine, providing innovative technologies to cover all your testing needs.

# # #

About Randox:

• Randox is an international diagnostic solutions company, headquartered in the UK with 25 offices worldwide.
• Randox is a market leader in developing, manufacturing and marketing clinical diagnostic products including the revolutionary Biochip Array Technology, clinical chemistry analysers and reagents, quality controls and EQA as well as a complete life science range.
• Randox provides innovative products to over 30,000 customers worldwide ranging from hospitals and research laboratories to veterinary laboratories, pharmaceutical companies and crime labs.
• Re-invests significantly into Research and Development.
• 5 x Winners of the Queen’s Award for Enterprise.
- Invest NI Innovator of the Year 2009
- Manufacturing Excellence Award 2009 for Product Innovation
• Randox is revolutionising healthcare through continuously improving diagnostic solutions.